Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : ZonMw | ACE Pharmaceuticals BV
Deal Size : Inapplicable
Deal Type : Inapplicable
LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2023
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : ZonMw | ACE Pharmaceuticals BV
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Cadila Receives Final Approval from USFDA for Liothyronine Sodium Tablets
Details : Liothyronine is a man-made form of thyroid hormone which is used to treat an underactive thyroid (hypothyroidism). Zydus Cadila has received final approval from the USFDA to market Liothyronine Sodium Tablets USP, 5 mcg, 25 mcg, and 50 mcg (US RLD: Cytom...
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 23, 2021
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Attikon Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2020
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Attikon Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Tel Aviv Sourasky Medical Center (Ichilov Hospital)
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2016
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Tel Aviv Sourasky Medical Center (Ichilov Hospital)
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase III
Sponsor : CRDF Global | Osypka Medical | Dalim BioTech
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral Triiodothyronine for Children Undergoing Cardiopulmonary Bypass in Indonesia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 13, 2015
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Sponsor : CRDF Global | Osypka Medical | Dalim BioTech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of T3 Therapy in Patients With Hypothyroidism
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
February 27, 2013
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
April 20, 2012
Lead Product(s) : Liothyronine Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable